Record-breaking support for infectious disease and vaccine development

INFECTIOUS DISEASE EXPERTISE FOR A NEW ERA
null

20x faster

Patient enrollment rate compared to competing sites for global COVID-19 trials
null

1,000+

Enrolled patients in infectious disease studies
null

30M+

Data points captured within two months of activity

Leveraging more than 20 years of experience in clinical trials, Elixia worked with agility to provide robust development support for COVID-19 programs.

We’ve since extended therapeutic coverage to other infectious-disease related studies. It’s a new era in this area of clinical development.

Elixia was well-positioned with relevant capabilities to respond to the growing global need for pharmaceutical partners to develop COVID-19 treatment trials. Elixia played an integral role in achieving global recruitment target goals with world-record speed in the midst of the pandemic.

WE ARE PROUD TO HAVE PARTNERED WITH

Our research areas

Elixia’s research sites and physician investigators have successfully completed studies in many therapeutic subcategories in the infectious disease space.

null

COVID-19 Prophylaxis

null

Hepatitis

null

COVID-19 Treatment

null

HIV

null

Flu Vaccine